DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Advil Dual Action With Acetaminophen is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in ADVIL DUAL ACTION WITH ACETAMINOPHEN is acetaminophen; ibuprofen. There are sixty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the acetaminophen; ibuprofen profile page.
Summary for ADVIL DUAL ACTION WITH ACETAMINOPHEN
|Finished Product Suppliers / Packagers:||2|
|Formulation / Manufacturing:||see details|
|What excipients (inactive ingredients) are in ADVIL DUAL ACTION WITH ACETAMINOPHEN?||ADVIL DUAL ACTION WITH ACETAMINOPHEN excipients list|
|DailyMed Link:||ADVIL DUAL ACTION WITH ACETAMINOPHEN at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for ADVIL DUAL ACTION WITH ACETAMINOPHEN
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ADVIL DUAL ACTION WITH ACETAMINOPHEN
Identify potential brand extensions & 505(b)(2) entrants
|Mayo Clinic||Phase 2|
|Baylor College of Medicine||Phase 1|
|University of Texas Southwestern Medical Center||Phase 1|
Pharmacology for ADVIL DUAL ACTION WITH ACETAMINOPHEN
Anatomical Therapeutic Chemical (ATC) Classes for ADVIL DUAL ACTION WITH ACETAMINOPHEN
ADVIL DUAL ACTION WITH ACETAMINOPHEN is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ADVIL DUAL ACTION WITH ACETAMINOPHEN is ⤷ Try it Free.
This potential generic entry date is based on NEW PRODUCT.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
FDA Regulatory Exclusivity protecting ADVIL DUAL ACTION WITH ACETAMINOPHEN
Exclusivity Expiration: ⤷ Try it Free
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Glaxosmithkline||ADVIL DUAL ACTION WITH ACETAMINOPHEN||acetaminophen; ibuprofen||TABLET;ORAL||211733-001||Feb 28, 2020||OTC||Yes||Yes||⤷ Try it Free||⤷ Try it Free||⤷ Try it Free|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|